A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

2 1

What is this study about?

This study focuses on individuals living with Hidradenitis Suppurativa, a chronic skin condition characterized by painful, red lumps under the skin that can form abscesses or tunnels. The purpose of the study is to evaluate the safety and effectiveness of a medication called ritlecitinib, also known as PF-06651600, compared to a placebo.

During the study, participants will be assigned to receive either the active medication or a placebo in a randomized way, meaning the group assignment is decided by chance. The process is double-blind, which means neither the participants nor the researchers know which substance is being administered. The study will last for a total of 16 weeks, during which time the effects of the treatment on the skin and symptoms will be monitored.

Who Can Join the Study?

You must be between 18 and 75 years old.
You must have a confirmed medical diagnosis of Hidradenitis Suppurativa (a chronic skin condition that causes painful lumps under the skin) for at least 6 months.
Your condition must be moderate to severe, which means you have Hurley Stage II or III (levels used to describe how much the skin is affected by the disease) and at least 5 inflammatory lesions (painful, red, swollen bumps like abscesses or nodules) located in at least 2 different body areas.
You must have either not seen enough improvement after taking systemic therapy (medicine that travels through the entire body, such as a pill) for at least 4 weeks, or you must have a medical reason why you cannot take this type of medicine.

Who Cannot Join the Study?

Having 20 or more draining fistulas, which are abnormal tunnels or passages that form under the skin and leak fluid.
Having other skin conditions that might make it difficult to tell if the treatment is working for your specific condition.
Having previously used a JAK inhibitor or a BTK inhibitor, which are types of medicines used to change how the immune system works.
Having any serious medical or mental health illnesses.
A limited number of people in the study may have previously used anti-TNF-α, IL-17 inhibitors, or IL-23 inhibitors, which are specific types of medications used to calm an overactive immune system.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Dermedic Jacek Zdybski	Ostrowiec Swietokrzyski	Poland
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany
Technische Universitaet Dresden	Dresden	Germany
Royalderm Agnieszka Nawrocka	Warsaw	Poland

Other Sites

Site Name	City	Country
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitario Puerta Del Mar	Cadiz	Spain
Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.	Szczecin	Poland
Complexo Hospitalario Universitario De Pontevedra	Pontevedra	Spain
University General Hospital Of Heraklion	Heraklion	Greece
Hospital Universitario Virgen De Las Nieves	Granada	Spain
Klinika Ambroziak Sp. z o.o.	Warsaw	Poland
Soft Skin Medical Center Dr Elzbieta Wojtowicz-Prus	Wroclaw	Poland
Universitaetsklinikum Schleswig-Holstein AöR	Kiel	Germany
General University Hospital Of Larissa	Larissa	Greece
Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie	Rzeszow	Poland
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p.	Wroclaw	Poland
General Hospital Of Thessaloniki Papageorgiou	Thessaloniki	Greece
Andreas Syngros Hospital Of Venereal And Dermatological Diseases	Athens	Greece
Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II W Sosnowcu Sp. z o.o.	Sosnowiec	Poland
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara	Chaidari	Greece
Uzmkboqoxk Myunsqd Cfksoy Hzaivwspbdqufdgag	Hamburg	Germany
Cyjawut Bmvlu Kmvraqmmzfb Ptekjpig Sgw z omiu	Gdansk	Poland
Twpypofs Shl z ojez	Piotrkow Trybunalski	Poland
Peeowuslx Ibkordlf Mmszfdzk Mnlzogkmbrpt Soysw Wzquxiviegwp I Ajdtvvpangllp	Warsaw	Poland
Aqzcjn Mdxkafm Ctdvun Sesa	Thessaloniki	Greece
Gdpbrz Uzjyuibaur Fmwqprjrx	Frankfurt	Germany
Utedtoclhbwhkylwlpbep Wvuvcgyoo Aeg	Wuerzburg	Germany

Trial status

Country	Status	Recruitment Start
Germany	Recruiting	21.04.2026
Greece	Not yet recruiting	21.04.2026
Poland	Recruiting	21.04.2026
Spain	Recruiting	21.04.2026

Trial locations

Ritlecitinib is an oral medication taken in capsule form that is being tested to see if it can help reduce the symptoms and improve the skin condition in adults living with moderate to severe hidradenitis suppurativa.

Hidradenitis suppurativa – This is a chronic skin condition that causes painful lumps to form underneath the skin. These lumps typically appear in areas where skin rubs together, such as the armpits or groin. As the condition progresses, these lumps can break open and drain fluid or pus. Over time, the inflammation may lead to the formation of tunnels or tracts under the skin. These connections can link multiple lumps together and cause scarring. The disease often occurs in recurring episodes.

Trial ID:

2025-522705-37-00

Protocol code:

B7981119

NCT ID:

NCT07228390

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?